CClinicalTrials.gg
Status unknownNCT05776355Updated Mar 28, 2023

NKG2D CAR-NK & Ovarian Cancer

An interventional study of NKG2D CAR-NK in Ovarian Cancer, sponsored by Hangzhou Cheetah Cell Therapeutics Co., Ltd. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-28.

Sponsored by Hangzhou Cheetah Cell Therapeutics Co., Ltd · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This trial will explore the maximum tolerated dose (MTD)of NKG2D CAR-NK cells in the treatment of platinum-resistant, relapsed epithelial ovarian cancer in a dose-escalation manner, and observe the clinical safety and efficacy.

02

Conditions studied

  • Ovarian Cancer

Keywords

  • CAR-NK
03

In context

Ovarian Neoplasms

2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.

This study's planned enrollment of 18 is below the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Hangzhou Cheetah Cell Therapeutics Co., Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 18 years and older
  2. Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer
  3. Documented platinum resistant epithelial ovarian cancer with at least 1 measurable lesion
  4. ECOG performance status of 0-2
  5. Adequate organ function defined as: ANC≥1.5×109/L, PLT≥75×109/L, TBIL≤1.5×ULN, AST≤2.5×ULN, ALT≤2.5×ULN, Cr≤1.5×ULN
  6. Negative urine or serum pregnancy test within 7 days prior to treatment for women of childbearing age
  7. Life expectancy ≥ 12 weeks from the time of enrollment
  8. All patients must have the ability to understand and willingness to sign a written informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Patients with history of other active malignancy within 1 year prior to enrollment;
  2. Patients with central nervous system (CNS) metastases. History of any CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, any autoimmune disease with CNS involvement, posterior reversible encephalopathy syndrome, or cerebral edema;
  3. Patients with ongoing uncontrolled serious infection, clinically significant cardiac disease (i.e., symptomatic congestive heart failure, myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, uncontrolled cardiac arrhythmia), poorly controlled pulmonary disease (no clinically significant pleural effusion), or psychiatric illness/social situations that would limit compliance with study requirements within 12 months prior to enrollment;
  4. Patients with immunologic deficiency or autoimmune diseases;
  5. Known human immunodeficiency virus (HIV) seropositivity or active hepatitis B or C infection. A history of hepatitis B or C is permitted if the viral load is undetectable by quantitative assay;
  6. Patients who are breastfeeding or pregnant;
  7. Patients, who in the opinion of the investigator, may not be able to comply with the monitoring requirements of the study;
  8. Patients participated in another investigation treatment study 4 weeks prior to enrollment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Ovarian cancer

    Biological: NKG2D CAR-NK

Interventions

  • BiologicalNKG2D CAR-NK

    Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion

06

What researchers measure

Primary outcomes

  1. DLT

    Dose-Limiting Toxicity

    Time frame: 28 days

  2. MTD

    Maximal Tolerable Dose

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05776355
Lead sponsor
Hangzhou Cheetah Cell Therapeutics Co., Ltd
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
Mar 2023 (estimated)
Primary completion
Apr 2024 (estimated)
Completion
Sep 2024 (estimated)
Last update
Mar 28, 2023

Study contacts

Zhu JianQing, MD
Contact
zjq-hz@126.com
571-88128118 ext. 86
Zhu JianQing, MD
principal investigator · Zhejiang Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion